Examkin

Question

Difficulty: Very hardDepressive Disorders

A 32-year-old woman comes to the outpatient clinic 4 months postpartum for a follow-up evaluation of depressive symptoms. Two weeks ago, she presented with a 4-week history of profound despondency, early morning awakenings, anorexia with a 3-kg (6.6-lb) weight loss, and feeling worse in the morning. She reported that these symptoms made it exceedingly difficult to get out of bed and properly care for her infant. At that time, she was diagnosed with major depressive disorder and started on escitalopram 10 mg daily. Today, she states, "The medication isn't working. I still feel incredibly depressed, but now I also feel extremely restless, jittery, and my thoughts are racing." Vital signs are within normal limits. On examination, the patient appears visibly agitated, is pacing the room, and exhibits rapid speech. Upon detailed psychiatric review, she mentions that during her second year of college, she experienced a spontaneous 6-day period where she felt "incredibly energized," slept only 3 hours per night without fatigue, and impulsively maxed out two credit cards on unnecessary clothing. That episode resolved without medical intervention. Which of the following is the most appropriate next step in pharmacotherapy?

  1. A
    Continue escitalopram and schedule a follow-up in 4 weeks
  2. B
    Increase the dosage of escitalopram to 20 mg daily
  3. Discontinue escitalopram and initiate quetiapineAnswer
  4. D
    Discontinue escitalopram and initiate venlafaxine
  5. E
    Continue escitalopram and add bupropion

Answer

Discontinue escitalopram and initiate quetiapine
This patient initially presented with a major depressive episode and was appropriately treated for unipolar depression based on the initial assessment. However, her current presentation of profound depression mixed with severe agitation, pacing, and racing thoughts shortly after starting an SSRI is highly suspicious for a treatment-emergent mixed state. A detailed history reveals a prior spontaneous 6-day episode of decreased need for sleep, increased energy, and impulsivity, which meets the DSM-5 criteria for a hypomanic episode. Therefore, her correct diagnosis is Bipolar II disorder. Antidepressant monotherapy (like escitalopram) is contraindicated in bipolar disorder due to the risk of mood destabilization. The most appropriate next step is to discontinue the offending SSRI and initiate a medication that is FDA-approved for acute bipolar depression, such as the atypical antipsychotic quetiapine.

Step-by-Step Solution

1
Evaluate the patient's past psychiatric history from the clinical interview.
The patient describes a distinct 6-day period of elevated mood, decreased need for sleep, and impulsive behavior in college.
Identifying past episodes of abnormally elevated mood is crucial to differentiate unipolar major depressive disorder from bipolar disorder. A 4-to-6 day period of these symptoms without marked impairment or hospitalization defines a hypomanic episode, establishing a diagnosis of Bipolar II disorder.
2
Assess the patient's current response to the prescribed SSRI.
After 2 weeks of escitalopram, the patient has worsening depression alongside new-onset severe agitation, restlessness, pacing, and racing thoughts.
When a patient with an underlying bipolar spectrum disorder is treated with antidepressant monotherapy, it can precipitate mood destabilization, leading to a mixed state (depressive symptoms combined with psychomotor agitation and racing thoughts) or a full manic switch.
3
Determine the appropriate pharmacologic intervention.
The SSRI must be stopped, and a medication indicated for acute bipolar depression should be started.
Continuing the SSRI will exacerbate the mixed state. Quetiapine, lurasidone, or a combination of olanzapine and fluoxetine are first-line, FDA-approved treatments for acute bipolar depression that provide efficacy without the high risk of mood destabilization.

Key Concept

Patients presenting with depressive episodes must be carefully screened for a history of mania or hypomania. Antidepressant monotherapy in patients with unrecognized Bipolar II disorder can induce severe agitation, mixed states, or manic switches, necessitating immediate cessation of the antidepressant and initiation of a bipolar-specific agent.
Rate this question

Topics

Depressive Disorders

More questions from this topic